Proof-point cadence: the last promised marker just landed, and the next one is already on the clock
The model's full reasoning — Q3 2023 call → NOWe need to determine if management presents a live, checkable sequence of proof points with both a marker just delivered and a next marker named and near. Let's analyze the transcript. Management discusses several operational achievements: - Launch of FUROSCIX in late February, second full quarter of commercial availability. - Q3 net revenue of $3.8 million, up 138% sequentially. - Direct sales to IDNs captured for first time. - Added 12 sales territories at end of Q3, bringing to 66. - Payer agreements: late October agreement with large IDN providing unrestricted access to 8 million lives; as of Nov 1, added on formulary with government retiree payer, adding 1.1 million lives. - FDA feedback on three initiatives: Class 4 indication filed in early October; auto-injector PK study planned 2024, sNDA by end of 2024; CKD indication feedback, no additional clinical studies needed, plan to advance. Now, is there a specific, concrete operational step that was just completed? Yes, several: the IDN agreement, the formulary addition, the filing for Class 4 indication, the addition of sales territories. But are these presented as checkpoints on a path previously described? The company had previously stated goal of 75% heart failure patients with fixed co-pays of $100 or less. The payer agreements move towards that. Also, the Class 4 indication expansion was previously mentioned as a key initiative. So these are checkpoints. But the question asks for a "MARKER JUST DELIVERED" - a specific, concrete operational step that was previously set out to accomplish and has just been completed. For example, the filing for Class 4 indication in early October is a concrete step. Also, the IDN agreement is a concrete step. The addition of sales territories is a step. Now, the "NEXT MARKER IS NAMED AND NEAR" - the next concrete step on that same forward path with approximate timing. For example, for the Class 4 indication, they filed in early October, and they are awaiting FDA approval? Actually, they filed, so the next step would be FDA approval, but that's not in their control. They might mention next steps like data from PK study in 2024, sNDA by end of 2024 for auto-injector. For CKD, they plan to advance. But are these near-term? They are within the coming year. But the question is about a coherent posture where management presents a sequence of proof points.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CMPS | COMPASS Pathways plc | Q3 2023 | 2023-11-04 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| HIW | Highwoods Properties, Inc. | Q4 2022 | 2023-02-08 | B |
| TCBI | Texas Capital Bancshares, Inc. | Q2 2021 | 2021-07-21 | F |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| SCVL | Shoe Carnival, Inc. | Q4 2017 | 2018-03-27 | C+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| INSM | Insmed Incorporated | Q4 2017 | 2018-02-23 | B |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
XOM · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES Management presents a live, checkable sequence of proof points. In Neil Chapman's remarks, he explicitly notes that the Coral Floating LNG project is "progressing on schedule" and that "fabrication of the hull is expected to start in the third quarter of this year" — a concrete, near-term operational checkpoint 3–4 months away. Immediately prior, he states that "earlier this month, we announced that the development plan for the first phase has been submitted," treating that submission as the just-completed marker on the same path. He anchors the next step as "targeting final investment decision in 2019" with 2024 first LNG, presented as scheduled and already in motion rather than aspirational. This forms one coherent posture: the company is executing a verifiable execution sequence on the Mozambique LNG opportunity, with the development-plan submission just cleared and FID locked for 2019. Other examples (Baytown ethane cracker operations begun yesterday; 50 new Permian wells brought to sales in the quarter) exist, but the Mozambique LNG thread satisfies both required elements on a single forward path. No other elements (financial beats, routine maintenance, or analyst questions) are used to construct the sequence.
MKC · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing the Frank's and French's integration as a completed checkpoint ("With the acquisition and integration complete"), then immediately naming and anchoring the next concrete steps on the same path — such as launching the first dedicated mustard campaign in the U.S. (kicked off this week during the call) and 2018 U.S. national TV advertising for Frank's in the second half — as scheduled, in-motion activities that will drive further growth. This is presented as one coherent execution sequence rather than isolated results. Other elements like distribution gains and summer grilling promotions are tied directly to this progression. No routine or vague items qualify; 2018 advertising and marketing acceleration are explicitly tied to the post-integration trajectory.
CMPS · Q3 2023 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing progress as a live execution sequence: the open-label PTSD Phase II study has just reached full recruitment (a concrete checkpoint passed), and they explicitly name the next marker — top-line readout this year — as the immediate follow-on step already in motion and scheduled within the coming months. This is presented as part of the same forward trajectory they are tracking, alongside the TRD Phase III where site initiations (3/4 of COMP005) are described as continuing to advance toward the summer 2024 readout.